Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Gene Evolution Process Discovered
One of the mechanisms governing how our physical features and behavioural traits have evolved over centuries has been discovered by researchers at the University of Leeds.

Economy Squeezing Access To Health Care
As unemployment rises, many Florida women are "turning to federally subsidized mammograms and pap smears, and county health officials are worried they could be overwhelmed," The Orlando Sentinel reports. "Since 1990, the Centers for Disease Control [and Prevention] has provided free and low-cost mammograms and pap smears to uninsured or underinsured women between 40 and 64 years old. In Florida, only women 50 to 64 years old qualify. Although the number of women screened in Florida through this federal program has increased through the years, unemployment in women 55 to 64 years old has nearly doubled, from 3.4 percent in 2008 to 6.3 percent now. Demand always has exceeded available services - only 15 percent of eligible women get the breast exams, according to the CDC - but the number of women who will now qualify for the free tests is expected to outstrip the funding provided by Congress" (Maza, 7/15).
News of the day
Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data At ASCO Annual Meeting
Cougar Biotechnology, Inc. (NASDAQ:CGRB) announced that results from ongoing Phase II clinical trials of Cougar"s investigational drug CB7630 (abiraterone acetate) were presented at the 2009 ASCO Annual Meeting that is currently taking place in Orlando, Florida. The data were released today in three poster presentations. These presentations are further detailed below:
Medical Devices

New Data Supports Significant Economic And Clinical Value Of MENOPUR(R) In IVF

New data from an economic analysis presented today at this year"s European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in vitro fertilisation (IVF) treatment MENOPUR (highly-purified human menopausal gonatropin or HP-hMG) offered considerable cost-savings over recombinant follicle stimulating hormone (rFSH).1 The cost-effectiveness of HP-hMG compared with rFSH suggested by this data could make it a more attractive choice for use in infertility treatment within a fixed healthcare budget. In today"s difficult global financial situation, the cost-effectiveness of infertility treatments, such as IVF, is more important than ever. Experiencing fertility problems is deeply distressing and isolating for couples and the cost of treatment is one of many considerations for people seeking treatment. A recent audit of European infertility patient groups showed that infertile couples are calling for clear information on the cost-effectiveness, as well as the efficacy of individual treatments.2 HP-hMG and rFSH are two commonly used hormonal therapies belonging to the class of drugs known as gonadotropins that enhance egg production in IVF treatment. HP-hMG, contains both FSH and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). In contrast, rFSH is a recombinant product and contains only rFSH. "Until recently, discussions regarding funding for infertility treatment services have been hindered by a relative paucity of economic studies of the specific treatments," points out study investigator Dr Jaro Wex from PharmArchitecture, UK. "Our new study compared success rates and value for money of gonadotropins in IVF and this work is likely to have a major impact on the decision-making process with respect to IVF treatment. The study showed that HP-hMG is a more attractive option than rFSH within a fixed budget, as it offers considerable cost savings over rFSH, not only in terms of costs per treatment cycle, but also in costs per live births." Health economic data The new study determined the cost-effectiveness of different gonadotropins in IVF cycles involving frozen embryo transfers using a simulation model. The economic evaluation compared HP-hMG and rFSH using individual patient data (n=986) pooled from two large, randomised, multi-national, non-inferiority trials (EISG3 and MERiT4)5. The simulation model used both live-birth data for the compared products and published UK costs of IVF related medical res. The main objectives were to determine for each patient starting treatment consisting of one fresh and up to two cryo or fresh cycles: (1) number of live-births (2) average cost of treatment; (3) average cost per live-birth; (4) incremental cost-effectiveness; (5) impact of inclusion of maternal and neonatal costs arising from successful pregnancies. After a sequence of one fresh and up to two frozen or fresh cycles, the cumulative live-birth rate was 53.7% for HP-hMG and 44.6% for rFSH (pMENOPUR MENOPUR belongs to a class of drugs known as gonadotropins and contains both FSH (follicle stimulating hormone) and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). HP-hMG is used to stimulate the development of multiple follicles in women participating in an ART programme. HP-hMG is also used to treat infertility in women caused by anovulation (low-level production of eggs). MENOPUR is used by over 75,000 patients each year and is currently licensed in over 50 countries across the world Ferring Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009